ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical ...
If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...
Melanoma is the most common form of skin cancer, but for patients with advanced melanoma who no longer respond to standard ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class ...
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new preclinical and translational data from multiple investigational programs at two ...
STOCKED in every high street pharmacy in Britain, it is a drug that’s meant to ease pain – not cause it. And yet, an ...
Clinical and Pharmacology Data Presented at ACR Convergence 2025In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback